{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-07T01:24:38.127939+00:00","company":{"ticker":"CNTX","cik":1842952,"company_name":"Context Therapeutics Inc."},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"7ca284ede197b6d84b78373d4c3f51ac7af72956","cik":1842952,"ticker":"CNTX","company_name":"Context Therapeutics Inc.","filed_at":"2026-03-13T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-03-11","item_codes_triggered":["5.03"],"summary_text":"Delaware court invalidated charter provisions for staggered three-year board terms and for-cause removal; company filed a Certificate of Correction and directors will now serve until the 2026 annual meeting and may be removed with or without cause."},"claim":"Context Therapeutics Inc.: Delaware court invalidated charter provisions for staggered three-year board terms and for-cause removal; company filed a Certificate of Correction and directors will now serve until the 2026 annual meeting and may be removed with or without cause (effective 2026-03-11).","evidence_excerpt":"On March 11, 2026, the Court approved the Stipulated Judgment, pursuant to which (i) Article V, Section 2 of the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”), which provides that the Company’s directors shall serve for a term of three years, and (ii) Article VI, Section 1 of the Charter, which provides that the directors of the Company may be removed from office only for cause, were determined to be invalid and unenforceable.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-017691","anchor_url":"https://secwatch.observer/filing/0001628280-26-017691#claim-7ca284ede197b6d84b78373d4c3f51ac7af72956","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026017691/0001628280-26-017691-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"89ae151671131cb7c409ea6a6fabfcd0afc5d1b3","cik":1842952,"ticker":"CNTX","company_name":"Context Therapeutics Inc.","filed_at":"2025-09-02T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-02-23","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-28","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Context Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 28, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Extension Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026 (the “Extension Deadline”), to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Extension Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. As previously disclosed, on February 27, 2025, the Company received written notice from Nasdaq stating that","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001842952-25-000085","anchor_url":"https://secwatch.observer/filing/0001842952-25-000085#claim-89ae151671131cb7c409ea6a6fabfcd0afc5d1b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000085/0001842952-25-000085-index.htm"},{"fact_type":"executive_change","fact_key":"70e6146073","cik":1842952,"ticker":"CNTX","company_name":"Context Therapeutics Inc.","filed_at":"2025-01-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-13","interim":false,"role":"Chairperson of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Andy Pasternak was appointed as Chairperson of the Board at Context Therapeutics Inc..","evidence_excerpt":"the Board appointed Andy Pasternak as a member and Chairperson of the Board, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001842952-25-000003","anchor_url":"https://secwatch.observer/filing/0001842952-25-000003#claim-70e6146073","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000003/0001842952-25-000003-index.htm"},{"fact_type":"executive_change","fact_key":"567f632015","cik":1842952,"ticker":"CNTX","company_name":"Context Therapeutics Inc.","filed_at":"2025-01-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-01-12","interim":false,"role":"Director","role_category":"director","successor_name":"Andy Pasternak","successor_named":true},"claim":"Richard Berman resigned as Director at Context Therapeutics Inc..","evidence_excerpt":"On January 10, 2025, Richard Berman gave notice of his resignation from the Board of Directors (the “Board”) of Context Therapeutics Inc. (the \"Company\"), effective as of January 12, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001842952-25-000003","anchor_url":"https://secwatch.observer/filing/0001842952-25-000003#claim-567f632015","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000003/0001842952-25-000003-index.htm"},{"fact_type":"executive_change","fact_key":"f2a8b8e82c","cik":1842952,"ticker":"CNTX","company_name":"Context Therapeutics Inc.","filed_at":"2024-09-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Luke Walker was appointed as Director at Context Therapeutics Inc..","evidence_excerpt":"On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee (\"Nominating Committee\") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001842952-24-000070","anchor_url":"https://secwatch.observer/filing/0001842952-24-000070#claim-f2a8b8e82c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000070/0001842952-24-000070-index.htm"},{"fact_type":"executive_change","fact_key":"9904baebda","cik":1842952,"ticker":"CNTX","company_name":"Context Therapeutics Inc.","filed_at":"2024-09-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Karen L. Smith was appointed as Director at Context Therapeutics Inc..","evidence_excerpt":"On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee (\"Nominating Committee\") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001842952-24-000070","anchor_url":"https://secwatch.observer/filing/0001842952-24-000070#claim-9904baebda","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000070/0001842952-24-000070-index.htm"},{"fact_type":"material_agreement","fact_key":"a2758fc8df668c6f963fe10afc070661b23d6a9b","cik":1842952,"ticker":"CNTX","company_name":"Context Therapeutics Inc.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"the purchasers named therein","effective_date":"2024-05-01","item_codes_triggered":["1.01"],"value_text":"approximately $100 million"},"claim":"Context Therapeutics Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $100 million (effective 2024-05-01).","evidence_excerpt":"On May 1, 2024, Context Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 59,032,259 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.55 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 5,482,741 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $1.549 per Pre-Funded Warrant.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001842952-24-000033","anchor_url":"https://secwatch.observer/filing/0001842952-24-000033#claim-a2758fc8df668c6f963fe10afc070661b23d6a9b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000033/0001842952-24-000033-index.htm"},{"fact_type":"governance_change","fact_key":"8f3131704218452fa5b028132a302ecd65831a2b","cik":1842952,"ticker":"CNTX","company_name":"Context Therapeutics Inc.","filed_at":"2024-03-21T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-03-19","item_codes_triggered":["5.03"],"summary_text":"Reduced quorum to one-third, eliminated stockholder list requirement, updated notice requirements for director nominations and proposals, and implemented procedural mechanisms related to Rule 14a-19."},"claim":"Context Therapeutics Inc.: Reduced quorum to one-third, eliminated stockholder list requirement, updated notice requirements for director nominations and proposals, and implemented procedural mechanisms related to Rule 14a-19 (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, the Board of Directors of the Company approved the amendment and restatement of the Company's Amended and Restated Bylaws (as so amended and restated, the “Bylaws”), primarily to (i) reduce the quorum necessary to hold a meeting of stockholders to one-third of the Company's capital stock issued and outstanding and entitled to vote, present in person or represented by proxy, (ii) eliminate the requirement to produce and keep a stockholder list for examination at each meeting of stockholders, (iii) update notice requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings (other than proposals to be included in the Company’s proxy materials pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) and (iv) implement certain procedural mechanisms related to stockholder nominations of directors under Rule 14a-19 (“Rule 14a-19”) under the Exchange","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001842952-24-000010","anchor_url":"https://secwatch.observer/filing/0001842952-24-000010#claim-8f3131704218452fa5b028132a302ecd65831a2b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000010/0001842952-24-000010-index.htm"},{"fact_type":"material_agreement","fact_key":"4a6c47018fa54081ecaa27e6bf708831b0532a10","cik":1842952,"ticker":"CNTX","company_name":"Context Therapeutics Inc.","filed_at":"2024-03-06T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Integral License Agreement","agreement_type":"collaboration","counterparty":"Integral Molecular, Inc.","effective_date":"2024-02-29","item_codes_triggered":["1.01"],"value_text":null},"claim":"Context Therapeutics Inc. amended Integral License Agreement with Integral Molecular, Inc. (effective 2024-02-29).","evidence_excerpt":"Context Therapeutics Inc. (the “Company”) amended its collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001842952-24-000005","anchor_url":"https://secwatch.observer/filing/0001842952-24-000005#claim-4a6c47018fa54081ecaa27e6bf708831b0532a10","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000005/0001842952-24-000005-index.htm"}]}